Formula Growth Ltd. Has $347,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Formula Growth Ltd. lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 88.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,810 shares of the medical equipment provider’s stock after selling 38,000 shares during the period. Formula Growth Ltd.’s holdings in Hologic were worth $347,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Benson Investment Management Company Inc. bought a new stake in Hologic during the 4th quarter worth about $4,832,000. Principal Financial Group Inc. raised its holdings in Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after purchasing an additional 1,606 shares during the period. Clean Yield Group boosted its position in shares of Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after buying an additional 238,222 shares in the last quarter. Finally, Stifel Financial Corp raised its stake in Hologic by 115.8% during the 3rd quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider’s stock worth $1,658,000 after buying an additional 10,924 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of HOLX opened at $57.56 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a 50-day moving average of $61.58 and a 200-day moving average of $70.82. The company has a market cap of $12.92 billion, a PE ratio of 18.16, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a one year low of $55.89 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Stephens restated an “overweight” rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Evercore ISI lowered their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and cut their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Finally, Raymond James restated an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.